Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 5,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: HIV Infection, Healthy
Interventions: Silymarin (milk thistle); Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Disease
Interventions: α1 Proteinase Inhibitor, Placebos; Biological · Drug
Lead sponsor: Institute for Human Genetics and Biochemistry; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Hiv
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Disease
Interventions: HAART regimen, 3TC or FTC monotherapy; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 8 Years to 24 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 7 more

Conditions: HIV Infection, Menopause
Interventions: Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Lipodystrophy, HIV Infections
Interventions: Tesamorelin, Placebo for Tesamorelin; Drug
Lead sponsor: Theratechnologies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Indio, California + 20 more

Conditions: HIV Infections, Histoplasmosis, Blastomycosis
Interventions: Itraconazole, Amphotericin B; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more

Conditions: HIV/AIDS, Substance Abuse
Interventions: Directly administered antiretroviral therapy; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Hartford, Connecticut • New Haven, Connecticut

Conditions: HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)
Interventions: Not listed
Lead sponsor: East Tennessee State University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 6 Months to 13 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV
Interventions: NIATx + ECHO; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: IV Drug Usage, HIV Infections, Hepatitis C
Interventions: Tele-Harm Reduction, off-site linkage; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Miami, Florida • Tampa, Florida

Conditions: HIV Infections
Interventions: Automated diary system; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania

Conditions: HIV Infection
Interventions: atazanavir, lopinavir/ritonavir; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: HIV Infections
Interventions: Hydroxyurea, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 18
States / cities: San Diego, California • San Francisco, California • Stanford, California + 11 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: fosamprenavir (GW433908), ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 13 Years and older
Enrollment: 753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 10
States / cities: Fountain Valley, California • San Francisco, California • Denver, Colorado + 6 more

Conditions: Substance Abuse, HIV Risk, Shame, Guilt, Empathy, Criminogenic Thinking
Interventions: Impact of Crime Modules, TAU; Behavioral
Lead sponsor: George Mason University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Kaposi's Sarcoma
Interventions: VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 2
States / cities: Miami, Florida • St Louis, Missouri

Conditions: HIV Infections
Interventions: Infeccion de Amor (Love Infection); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Engerix B, Twinrix for ATN 024, Recombivax, Twinrix for ATN 025; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 25 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more

Conditions: Chronic Disease, HIV/AIDS, Liver Diseases, Inflammatory Bowel Diseases, Cardiovascular Diseases, Rheumatic Diseases, Neurodegenerative Diseases
Interventions: Non-interventional (observational only); Other
Lead sponsor: Epividian; Industry
Eligibility: 0 Years and older
Enrollment: 2,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2035
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV (Human Immunodeficiency Virus)
Interventions: Health Management App with symptom strategies, Control App; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: PML, AIDS
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more

Search by objective public record fields.

The Effect of Milk Thistle on the Pharmacokinetics of Indinavir

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

Adherence and Clinical Correlates in Persons With HIV on TAF

Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy

Menopausal HT for Women Living With HIV (HoT)

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

Directly Observed Therapy for Community-Released HIV+ Prisoners

Prevalence of HIV-associated Neurocognitive Disorders (HAND) in a School of Medicine HIV/AIDS Outpatient Clinic

A Study of 1592U89 in HIV-Infected Children

Peru Decentralized HIV Care

Tele-Harm Reduction

Microbicides Acceptability Among Sexually Active Young Women

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Victim Impact Modules for Jail Inmates

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy

Love Infection: A Dramatized Story Intervention (Telenovela/Soap Opera) for HIV Prevention

Immunologic Memory (Supp. of ATN 024)

Observational Pharmaco-Epidemiology Research & Analysis

mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV)

Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome